Raph L Hamers

Summary

Publications

  1. ncbi request reprint The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa
    Raph L Hamers
    PharmAccess Foundation, Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 13:625-39. 2008
  2. ncbi request reprint Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review
    Raph L Hamers
    PharmAccess Foundation, Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 14:619-29. 2009
  3. doi request reprint HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia
    Raph L Hamers
    PharmAccess Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 55:95-101. 2010
  4. doi request reprint Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine
    Raph L Hamers
    Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    Antivir Ther 16:115-8. 2011
  5. doi request reprint Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study
    Raph L Hamers
    PharmAccess Foundation, Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands
    Lancet Infect Dis 12:307-17. 2012
  6. doi request reprint Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa
    Kim C E Sigaloff
    Department of GlobalHealth, University of Amsterdam, Amsterdam, The Netherlands
    J Infect Dis 205:1739-44. 2012
  7. doi request reprint HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes
    Raph L Hamers
    Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands PharmAccess Foundation, Amsterdam, The Netherlands Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands Department of Blood Borne Infections, Sanquin, Amsterdam, The Netherlands Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa Lancet Laboratories, Johannesburg, South Africa Lusaka Trust Hospital, Lusaka, Zambia Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa Muelmed Hospital, Pretoria, South Africa and Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 64:174-82. 2013
  8. doi request reprint Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries
    Kim C E Sigaloff
    PharmAccess Foundation, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam Institute for Global Health and Development, The Netherlands
    Clin Infect Dis 54:S294-9. 2012
  9. doi request reprint Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies
    Raph L Hamers
    PharmAccess Foundation, Academic Medical Center of the University of Amsterdam, The Netherlands
    Clin Infect Dis 54:1660-9. 2012
  10. doi request reprint Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa
    Kim C E Sigaloff
    PharmAccess Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 58:23-31. 2011

Collaborators

Detail Information

Publications18

  1. ncbi request reprint The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa
    Raph L Hamers
    PharmAccess Foundation, Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 13:625-39. 2008
    ..The report focuses on resistance associated with treatment, prevention of mother-to-child transmission and transmitted resistance. It also outlines priorities for public health action and research...
  2. ncbi request reprint Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review
    Raph L Hamers
    PharmAccess Foundation, Center for Poverty related Communicable Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 14:619-29. 2009
    ..This report reviews the current evidence for their utility...
  3. doi request reprint HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia
    Raph L Hamers
    PharmAccess Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 55:95-101. 2010
    ..To assess the mutational patterns and factors associated with baseline drug-resistant HIV-1 present at initiation of first-line antiretroviral therapy (ART) at 3 sites in Lusaka, Zambia, in 2007-2008...
  4. doi request reprint Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine
    Raph L Hamers
    Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
    Antivir Ther 16:115-8. 2011
    ..Emerging multi-NRTI resistance in sub-Saharan Africa would not only compromise second-line treatment options and the success of antiretroviral rollout, but could also contribute to the spread of drug-resistant variants worldwide...
  5. doi request reprint Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study
    Raph L Hamers
    PharmAccess Foundation, Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands
    Lancet Infect Dis 12:307-17. 2012
    ..We studied pretreatment drug resistance and virological, immunological, and drug-resistance treatment outcomes in a large prospective cohort...
  6. doi request reprint Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa
    Kim C E Sigaloff
    Department of GlobalHealth, University of Amsterdam, Amsterdam, The Netherlands
    J Infect Dis 205:1739-44. 2012
    ..The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure...
  7. doi request reprint HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes
    Raph L Hamers
    Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands PharmAccess Foundation, Amsterdam, The Netherlands Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands Department of Blood Borne Infections, Sanquin, Amsterdam, The Netherlands Department of Medical Microbiology, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa Lancet Laboratories, Johannesburg, South Africa Lusaka Trust Hospital, Lusaka, Zambia Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa Muelmed Hospital, Pretoria, South Africa and Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
    J Acquir Immune Defic Syndr 64:174-82. 2013
    ....
  8. doi request reprint Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries
    Kim C E Sigaloff
    PharmAccess Foundation, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam Institute for Global Health and Development, The Netherlands
    Clin Infect Dis 54:S294-9. 2012
    ..Additionally, data suggest an advantage of medication possession ratio over on-time antiretroviral drug pickup in identifying patients at risk for HIVDR development...
  9. doi request reprint Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies
    Raph L Hamers
    PharmAccess Foundation, Academic Medical Center of the University of Amsterdam, The Netherlands
    Clin Infect Dis 54:1660-9. 2012
    ..This cohort study examined patterns of drug-resistance mutations (DRMs) in individuals with virological failure on first-line ART at 13 clinical sites in 6 African countries and predicted their impact on second-line drug susceptibility...
  10. doi request reprint Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa
    Kim C E Sigaloff
    PharmAccess Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 58:23-31. 2011
    ..Frequencies of unnecessary switches, patterns of HIV drug resistance, and risk factors for the accumulation of nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations were evaluated...
  11. doi request reprint Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy
    Kim C E Sigaloff
    PharmAccess Foundation, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 29:925-30. 2013
    ..Methods to prevent treatment failure, including adequate pediatric formulations and alternative second-line treatment options, are urgently needed...
  12. doi request reprint Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya
    Kim C E Sigaloff
    PharmAccess Foundation, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 28:1033-7. 2012
    ..These findings justify increased vigilance with respect to TDR surveillance in African regions where ART programs are scaled-up in order to inform treatment guidelines...
  13. ncbi request reprint Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis
    Raph L Hamers
    PharmAccess Foundation, Department of Global Health, Academic Medical Center of the University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands
    AIDS 26:1663-72. 2012
    ....
  14. doi request reprint HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
    Raph L Hamers
    PharmAccess Foundation, Department of Global Health, Academic Medical Centre of University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
    Lancet Infect Dis 11:750-9. 2011
    ..We aimed to assess the prevalence of primary resistance in six African countries after ART roll-out and if wider use of ART in sub-Saharan Africa is associated with rising prevalence of drug resistance...
  15. doi request reprint Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa
    Raph L Hamers
    Department of Global Health, Academic Medical Center of the University of Amsterdam, PharmAccess Foundation, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands
    Curr Opin HIV AIDS 8:19-26. 2013
    ..This review provides an update of recent data on the development of HIV-1 drug resistance during treatment and its transmission in sub-Saharan Africa after the scale-up of antiretroviral therapy (ART)...
  16. pmc HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya
    Daniela Bezemer
    1 HIV Monitoring Foundation, Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 30:118-26. 2014
    ..GenBank comparison did not reveal other important transmission links. Our data suggest infrequent intermingling of MSM and heterosexual HIV-1 epidemics in Kenya...
  17. pmc Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study
    T Sonia Boender
    PharmAccess Foundation, P O Box 22700, 1100 DE, Amsterdam, The Netherlands
    AIDS Res Treat 2012:817506. 2012
    ..The problem of late disease at presentation requires a multifactorial approach, addressing both health system and individual-level factors...